

2022 Regular Session

SENATE BILL NO. 118

BY SENATOR TALBOT

HEALTH/ACC INSURANCE. Requires medical necessity for genetic testing of certain cancer mutations is based on nationally recognized clinical practice guidelines. (7/1/22)

1 AN ACT

2 To amend and reenact R.S. 22:1028.3(B)(2) relative to the medical necessity for genetic
3 testing of certain cancer mutations; to require medical necessity for genetic testing
4 of certain cancer mutations is based on nationally recognized clinical practice
5 guidelines; and to provide for related matters.

6 Be it enacted by the Legislature of Louisiana:

7 Section 1. R.S. 22:1028.3(B)(2) is hereby amended and reenacted to read as follows:

8 §1028.3. Required coverage for genetic testing for cancer

9 B.(1) * * *

10 (2) The coverage provided in this Section may be subject to annual
11 deductibles, coinsurance, and copayment provisions as are consistent with those
12 established under the health coverage plan. The coverage provided under this Section
13 may be subject to applicable evidence-based medical necessity criteria **that shall be**
14 **based on nationally recognized clinical practice guidelines from institutions like**
15 **the National Comprehensive Cancer Network, the American Cancer Society,**
16 **and the Food and Drug Administration labeling** ~~under the plan.~~

17 * * *

1 Section 2. This Act shall become effective on July 1, 2022.

The original instrument and the following digest, which constitutes no part of the legislative instrument, were prepared by Beth O'Quin.

DIGEST

SB 118 Original 2022 Regular Session Talbot

Present law provides coverage can be subject to annual deductibles, coinsurance, copayment provisions established under a health coverage plan and coverage for genetic testing of certain cancer mutations can be subject to applicable evidence-based medical necessity criteria under a health plan.

Proposed law removes provision that genetic testing of certain cancer mutations can be subject to evidence-based medical necessity criteria under a health plan but requires medical necessity for genetic testing of certain cancer mutations based on nationally recognized clinical practice guidelines from institutions like the National Comprehensive Cancer Network, the American Cancer Society, and the Food and Drug Administration labeling.

Effective on July 1, 2022.

(Amends R.S. 22:1028.3(B)(2))